Pleco Therapeutics BV
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pleco Therapeutics BV
Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
- Specialty Pharmaceuticals